Snus and Cancer: What the Scientific Evidence Shows

Swedish snus, a moist smokeless tobacco held under the upper lip, does not appear to cause oral or lung cancer based on the available epidemiological evidence. That finding alone separates it sharply from cigarettes. But the full picture is more complicated: a handful of studies point to elevated risks for certain gastrointestinal cancers, and a large pooled analysis links snus use to modestly higher overall mortality. The story depends heavily on which cancer site you ask about, which snus product is involved, and how the research handles the ever-present problem of separating snus effects from smoking history.

Oral Cancer Risk Looks Essentially Absent

The cancer most people associate with putting tobacco in your mouth is, paradoxically, the one for which the evidence is most reassuring. A pooled analysis of nine large prospective studies found that ever-use of snus was not associated with oral cancer, with an adjusted hazard ratio of 0.90. There was no clear trend linking heavier or longer use to higher risk, and among men who had never smoked, snus use still showed no connection to oral cancer.¹ An earlier cohort study of Swedish construction workers, a population with high snus use, came to the same conclusion: the relative risk for oral cancer among snus users was 0.8.²

This is worth pausing on because it confounds the intuition that tobacco against tissue should cause cancer at the contact site. The likely explanation is chemical rather than mechanical. Swedish snus is steam-pasteurized rather than fire-cured, and that process keeps levels of tobacco-specific nitrosamines and polycyclic aromatic hydrocarbons far lower than those found in many other smokeless products.³ These carcinogens are the primary drivers of cancer risk in traditional chewing tobacco and dry snuff, and Swedish snus simply delivers less of them.

Lung Cancer and the Comparison to Smoking

Because snus involves no combustion, there is no smoke and no tar entering the lungs. The construction worker cohort found a relative risk for lung cancer of 0.8 among snus users compared with people who had never used any tobacco.² That is what you would expect from a product that does not involve inhaling combustion byproducts.

Sweden’s population-level data reinforces this: the country has the lowest rate of tobacco-related mortality in Europe and the lowest incidence of male lung cancer, according to WHO data. Researchers have attributed much of that advantage to the widespread substitution of snus for cigarettes among Swedish men.⁴ Sweden is essentially the one country where a large share of men who would otherwise smoke switched to an oral product instead, and the mortality statistics reflect that shift.

Pancreatic Cancer Is Where the Evidence Gets Complicated

The construction worker cohort, published in The Lancet, found that snus use was independently associated with a doubled risk of pancreatic cancer (relative risk of 2.0 compared with men who had never used any tobacco).² That finding generated alarm when it was published in 2007 and is still widely cited.

But a much larger pooled analysis published a decade later, combining nine prospective studies, found no such association. After adjusting for smoking, current snus use carried a hazard ratio of 0.96 for pancreatic cancer, statistically indistinguishable from no effect at all.⁵ The pooled analysis had substantially more statistical power and was better able to separate snus use from confounding by smoking history.

How do you reconcile a doubled risk in one study with essentially no risk in a larger, more recent one? The construction worker study was a single cohort with limited ability to separate snus-only users from former smokers, and pancreatic cancer is rare enough that small amounts of uncontrolled confounding can skew results. The pooled analysis, by contrast, drew on multiple independent cohorts and adjusted more carefully for tobacco use patterns. Most researchers now treat the larger study as the better estimate. That said, a 2023 systematic review looking specifically at exclusive snus users noted that an increased risk of pancreatic cancer was still reported in some included studies, so the question has not been settled with complete certainty.⁶

Esophageal and Stomach Cancer Signals

One area where the evidence tilts more clearly toward concern is the upper gastrointestinal tract. A large Swedish study found that snus users who had never smoked had roughly three and a half times the risk of esophageal squamous cell carcinoma (relative risk of 3.5) and about 40 percent higher risk of noncardia stomach cancer compared with non-users.⁷ The authors acknowledged that confounding by unmeasured exposures could have inflated the associations but described the findings as “suggestive evidence for an independent carcinogenic effect of snus.”

These are not the cancer sites people typically worry about with oral tobacco, and the mechanism is not fully understood. One hypothesis is that swallowed saliva containing dissolved nitrosamines exposes the esophageal and stomach lining to low-level carcinogens over time. Esophageal squamous cell carcinoma is relatively uncommon in Sweden, so even a tripled relative risk translates to a small absolute number of cases. Still, the finding stands out as one of the more concerning signals in the snus-cancer literature.

Prostate Cancer Survival and Overall Cancer Mortality

A separate line of research has examined not whether snus causes specific cancers, but whether it affects survival once cancer has been diagnosed. Among men with prostate cancer, exclusive snus users had about a 24 percent higher risk of prostate cancer death compared with non-users of tobacco. The finding was more striking among men diagnosed with non-metastatic disease, where exclusive snus users had roughly three times the risk of dying from their prostate cancer.⁸

A broader study of over 40,000 cancer cases among Swedish construction workers found that exclusive snus users had a 15 percent increase in cancer-specific mortality compared with never-users of any tobacco. Interestingly, that was identical to the increase seen in exclusive smokers for cancer-specific death, though smokers had higher risks from other causes of death.⁹ A pooled analysis of eight prospective studies confirmed a modest association between current snus use and cancer mortality, with an adjusted hazard ratio of 1.12. The same analysis found that the mortality signal was stronger for cardiovascular disease and other causes than for cancer specifically.¹⁰

The prostate cancer findings have prompted speculation about whether nicotine itself affects tumor biology. Nicotine is not classified as a carcinogen, but laboratory studies suggest it can promote cell proliferation and inhibit apoptosis in some tumor types. Whether that mechanism explains the survival findings in humans is unresolved.

What the Mouth Lesions Do and Do Not Mean

Almost everyone who uses snus regularly develops a visible white or grayish change in the oral mucosa where the pouch sits. These lesions look alarming but are clinically benign. In a follow-up study of snuff users, every person who stopped using snus or moved the pouch to a different site showed complete healing at the original site, with normal tissue confirmed under microscopic examination.¹¹ Those who switched to portion-bags and reduced their exposure also showed measurable improvement. In short, the lesions are reversible and do not progress to cancer.

The more durable oral health concern is mechanical rather than malignant. Some snus users develop irreversible gingival recession at the placement site, sometimes with ulceration that exposes tooth roots. Those denuded roots are then vulnerable to decay and periodontal disease, and no good treatment currently exists for that kind of localized tissue loss.¹² So while snus does not appear to cause oral cancer, it is not without lasting effects on the tissue it contacts.

Why Which Product You Use Matters Enormously

Not all products called “snus” are chemically the same. The word gets applied to traditional Swedish snus, American imitations, and even loosely to unrelated smokeless tobacco products from South Asia and Africa. The cancer evidence described above comes almost entirely from studies of Swedish snus, which has been manufactured under increasingly strict quality controls for decades. In the late 1990s, Swedish manufacturers formalized those controls into a voluntary standard called GothiaTek, which set limits on levels of nitrosamines, heavy metals, and other unwanted compounds.¹³

The result is a measurably cleaner product. In lab comparisons, Swedish snus contained dramatically lower levels of carcinogenic polycyclic aromatic hydrocarbons than traditional American smokeless tobacco. The potent carcinogen benzo[a]pyrene averaged about 38 nanograms per gram in traditional moist snuff but was undetectable in most Swedish and newer American snus products.³

American snus products differ from Swedish snus in other ways beyond carcinogen content. A study comparing products sold in the United States with Swedish snus found that American versions had a much lower pH (around 6.5 versus 8.7), much lower moisture content, and dramatically less free nicotine available for absorption.¹⁴ The lower nicotine delivery makes American snus less effective as a cigarette substitute, which is why some researchers worry that promoting it for harm reduction could leave smokers in a pattern of dual use rather than a clean switch.

Dual Use With Cigarettes

A systematic review examining the health risks of using both snus and cigarettes found no special added danger from the combination. Of 51 tests for interaction effects between snus and cigarette use, only one reached statistical significance, and it was for gestational hypertension in a single dataset. The researchers noted that dual users actually tend to smoke fewer cigarettes than people who only smoke, which may partly explain the lack of additional risk.¹⁵ That said, any amount of continued smoking carries substantial cancer and cardiovascular risk. Snus does not neutralize the harm from cigarettes; it just does not appear to compound it.

Tobacco-Free Nicotine Pouches

The newest products in this space, tobacco-free nicotine pouches sold under brands like Zyn, Velo, and On!, contain pharmaceutical-grade nicotine in a plant-fiber base with no tobacco leaf at all. From a toxicological standpoint, they sit a step below snus on the risk spectrum. Chemical analyses consistently show lower levels of harmful constituents compared with both cigarettes and traditional snus.¹⁶

In laboratory studies, extracts from nicotine pouches did not trigger cytotoxicity or mutagenic responses, and genotoxic effects were minimal. By comparison, a cigarette reference product induced positive responses across multiple endpoints measuring oxidative stress, DNA damage, and cell stress.¹⁷ A clinical study found that snus users who switched to tobacco-free pouches saw their pre-existing oral mucosal lesions improve significantly over the study period.¹⁸

These products are too new for long-term epidemiological cancer data to exist. A systematic review noted that snus and nicotine pouches can still induce some DNA damage and changes in gene expression related to oxidative stress and cell proliferation at the cellular level.¹⁹ Whether those laboratory signals translate into clinical cancer risk after decades of real-world use is a question that will take years to answer.

The Missing Data on Women

Almost everything described above comes from studies of men, because snus use in Scandinavia has historically been overwhelmingly male. That leaves a major gap. The handful of studies that have examined smokeless tobacco and cancer in women come mostly from populations using very different products. A study of Black South African women who used dry nasal snuff found associations with cervical cancer and with cancer of the vulva among current users who had never smoked.²⁰ The proposed mechanism was intravaginal use of snuff, a practice with no parallel in Swedish snus use.

A broader systematic review of smokeless tobacco and cancer noted that associations with breast cancer, cervical cancer, lymphoma, and genitourinary tumors had been evaluated across various smokeless products with inconsistent results.²¹ The trouble is that “smokeless tobacco” encompasses dozens of products prepared and used in radically different ways. Generalizing from South Asian gutka or African dry snuff to Swedish snus is like generalizing from unfiltered hand-rolled cigarettes to nicotine patches because both involve tobacco-derived nicotine. The product matters, and we simply lack population-level cancer data on women who use Swedish-type snus specifically. As snus and nicotine pouch use rises among women in Scandinavia and elsewhere, that gap will eventually close, but for now the honest answer is that the evidence base applies almost exclusively to men.